East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Aripiprazole Orally Disintegrating Tablets USP, 10 mg and 15 mg. Aurobindo Pharma’s Aripiprazole Orally Disintegrating Tablets USP, are an AB-rated generic equivalent to the reference listed drug (RLD), Abilify Discmelt® Orally Disintegrating Tablets manufactured by Otsuka Pharmaceutical Co., Ltd.

Aripiprazole Orally Disintegrating Tablets USP, are indicated for:

• Schizophrenia
• Irritability Associated with Autistic Disorder
• Treatment of Tourette’s disorder